Uniqure NV (QURE) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Uniqure NV (QURE) has a cash flow conversion efficiency ratio of -0.072x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-16.40 Million) by net assets ($228.75 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see how much is Uniqure NV worth for the company's overall valuation and market capitalisation.
Uniqure NV - Cash Flow Conversion Efficiency Trend (2011–2024)
This chart illustrates how Uniqure NV's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Uniqure NV Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Uniqure NV ranked by their cash flow conversion efficiency. Explore QURE cash to earnings ratio to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Chongqing Iron & Steel Co Ltd Class A
SHG:601005
|
0.058x |
|
Bank of Qingdao Co. Ltd
F:4BQ
|
0.180x |
|
Perenti Ltd
AU:PRN
|
0.069x |
|
Boston Beer Company Inc
NYSE:SAM
|
0.112x |
|
Mitra Keluarga Karyasehat Tbk PT
JK:MIKA
|
0.053x |
|
Zhejiang Shaoxing RuiFeng Rural Commercial Bank Co Ltd
SHG:601528
|
-0.086x |
|
Shenzhen Chipscreen Biosciences Co
SHG:688321
|
0.001x |
|
Dongguan Aohai Technology Co
SHE:002993
|
0.067x |
Annual Cash Flow Conversion Efficiency for Uniqure NV (2011–2024)
The table below shows the annual cash flow conversion efficiency of Uniqure NV from 2011 to 2024. View Uniqure NV (QURE) share price today for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $-6.75 Million | $-182.73 Million | 27.063x | +3951.28% |
| 2023-12-31 | $207.67 Million | $-145.93 Million | -0.703x | -130.59% |
| 2022-12-31 | $476.01 Million | $-145.06 Million | -0.305x | -163.05% |
| 2021-12-31 | $595.78 Million | $287.96 Million | 0.483x | +187.44% |
| 2020-12-31 | $243.91 Million | $-134.83 Million | -0.553x | -80.96% |
| 2019-12-31 | $323.06 Million | $-98.68 Million | -0.305x | +27.85% |
| 2018-12-31 | $179.61 Million | $-76.04 Million | -0.423x | +40.75% |
| 2017-12-31 | $89.94 Million | $-64.27 Million | -0.715x | +37.02% |
| 2016-12-31 | $63.63 Million | $-72.19 Million | -1.134x | -889.30% |
| 2015-12-31 | $130.63 Million | $18.78 Million | 0.144x | +124.36% |
| 2014-12-31 | $52.39 Million | $-30.92 Million | -0.590x | +20.61% |
| 2013-12-31 | $7.68 Million | $-5.71 Million | -0.743x | -102.95% |
| 2012-12-31 | $-592.48K | $-14.91 Million | 25.172x | +290.73% |
| 2011-12-31 | $-3.36 Million | $-21.65 Million | 6.442x | -- |
About Uniqure NV
uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases in the United States. The company offers HEMGENIX that allows people living with hemophilia B to produce factor IX, which can lower the risk of bleeding. Its lead product candidate is AMT-130, a gene therapy candidate, which is in Phase I/II clinical study for the treatment of Huntington's disease. Th… Read more